0001376339-21-000067.txt : 20210525 0001376339-21-000067.hdr.sgml : 20210525 20210525083121 ACCESSION NUMBER: 0001376339-21-000067 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210525 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210525 DATE AS OF CHANGE: 20210525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 262792552 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 21957441 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: (770) 651-9100 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 8-K 1 mdxg-20210525.htm 8-K mdxg-20210525
0001376339false00013763392021-05-032021-05-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________

FORM 8-K
____________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 25, 2021
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
Florida001-3588726-2792552
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100
____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange
on which registered
Common Stock, $0.001 par value per shareMDXGThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐











Item 7.01    Regulation FD.

On May 25, 2021, MiMedx Group, Inc. (the "Company" or the "Registrant") issued a press release reminding shareholders to register to attend 2021 Annual Meeting of Shareholders to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21_vm. The press release also announced that the deadline to register to attend the annual meeting has been extended to 10:00 a.m. Eastern Time on May 26, 2021, and explains that Instructions on how to pre-register can be found within the Company’s 2021 definitive proxy statement or online at www.cesonlineservices.com/mdxg21_vm.

MiMedx disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 7.01 of this Current Report on Form 8-K. Information contained on the website www.cesonlineservices.com/mdxg21_vm is not incorporated by reference into this Current Report on Form 8-K. The information in the preceding paragraph, as well as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references Section 7.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.Description of Exhibit
99.1
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.


SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIMEDX GROUP, INC.
Date: May 25, 2021By:/s/ Peter M. Carlson
Peter M. Carlson
Chief Financial Officer


EX-99.1 2 ex991pre-registrationpress.htm EX-99.1 Document

Exhibit 99.1

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming
Virtual 2021 Annual Meeting of Shareholders

Deadline to Pre-Register Extended to May 26, 2021 at 10:00 a.m. Eastern

Pre-Registration Required to Attend Annual Meeting

Visit www.votemimedx.com for Instructions on How to Pre-Register

MARIETTA, Ga., May 25, 2021 – MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today reminded shareholders to pre-register for the upcoming 2021 Annual Meeting of Shareholders (“Annual Meeting”), by no later than 10:00 a.m. Eastern on Wednesday, May 26, 2021.

In order to attend the virtual meeting, all MIMEDX shareholders of record must pre-register by the extended deadline of 10:00 a.m. Eastern on May 26, 2021. Instructions on how to pre-register can be found within the Company’s 2021 definitive proxy statement or online at www.votemimedx.com.

MIMEDX will be holding its Annual Meeting virtually on May 27, 2021 at 10:00 a.m. Eastern Time at
www.cesonlineservices.com/mdxg21_vm. MIMEDX shareholders of record as of 5:00 p.m. Eastern Time on April 16, 2021 are entitled to vote at the Annual Meeting.

Important Information
The Company, its directors, director nominees and certain of its executive officers are participants in the solicitation of proxies from shareholders in respect of the Annual Meeting. The Company has filed a definitive proxy statement and associated WHITE proxy card in connection with the solicitation of proxies for the Annual Meeting with the SEC. Details concerning the nominees of the Company’s board of directors for election at the Annual Meeting are set forth in the definitive proxy statement. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, AS THEY CONTAIN IMPORTANT INFORMATION. Information regarding the identity of the Company’s participants and their respective interests in the matters to be voted on at the Annual Meeting, by security holdings or otherwise, are set forth in the definitive proxy statement and other documents filed with the SEC in connection with the Annual Meeting. Investors and shareholders can obtain a copy of the definitive proxy statement and other documents filed by the Company free of charge from the SEC’s website at www.sec.gov. The Company’s shareholders can also obtain, without charge, a copy of the definitive proxy statement and other relevant filed documents from the “SEC Filings” section of the Company’s website at www.mimedx.com.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a core business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.




Contacts:
Investors:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com

Media:
Hilary Dixon
Corporate Communications
770-651-9307
hdixon@mimedx.com


EX-101.SCH 3 mdxg-20210525.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mdxg-20210525_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 mdxg-20210525_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 mdxg-20210525_htm.xml IDEA: XBRL DOCUMENT 0001376339 2021-05-03 2021-05-03 0001376339 false 8-K 2021-05-25 MIMEDX GROUP, INC. FL 001-35887 26-2792552 1775 West Oak Commons Ct., NE Marietta GA 30062 770 651-9100 false false false false Common Stock, $0.001 par value per share MDXG NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page Document
May 03, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 25, 2021
Entity Registrant Name MIMEDX GROUP, INC.
Entity Incorporation, State or Country Code FL
Entity File Number 001-35887
Entity Tax Identification Number 26-2792552
Entity Address, Address Line One 1775 West Oak Commons Ct., NE
Entity Address, City or Town Marietta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30062
City Area Code 770
Local Phone Number 651-9100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol MDXG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001376339
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Document Sheet http://mimedx.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports mdxg-20210525.htm ex991pre-registrationpress.htm mdxg-20210525.xsd mdxg-20210525_lab.xml mdxg-20210525_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdxg-20210525.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mdxg-20210525.htm" ] }, "labelLink": { "local": [ "mdxg-20210525_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mdxg-20210525_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mdxg-20210525.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mdxg", "nsuri": "http://mimedx.com/20210525", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdxg-20210525.htm", "contextRef": "ic56690db25844d36a6bf99bc7fea27c2_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Document", "role": "http://mimedx.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mdxg-20210525.htm", "contextRef": "ic56690db25844d36a6bf99bc7fea27c2_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mimedx.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001376339-21-000067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-21-000067-xbrl.zip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end